Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Int J Clin Pharmacol Ther ; 58(10): 531-538, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32716292

RESUMO

OBJECTIVE: The aim of this study was to analyze the pharmacokinetics/pharmacodynamics (PK/PD) of higher-dose tigecycline (100 mg q12h) in severely infected intensive care unit (ICU) patients receiving continuous renal replacement therapy (CRRT). MATERIALS AND METHODS: In this prospective single-center observational study, severely infected patients receiving intravenous tigecycline were enrolled. They were divided into a CRRT group (7 cases) and a non-CRRT group (9 cases). The blood samples and CRRT ultrafiltrate were collected. The drug concentration in each sample was determined by a HPLC-UV method. The pharmacokinetic parameters were simulated and calculated with DAS 2.0. The PK/PD parameters were evaluated according to published data. The registration number of this study is NCT02931526 in ClinicalTrials.gov. RESULTS: In the non-CRRT group, Cmax, Cmin, and AUC0-24 were 1.00 ± 0.66 µg×mL-1, 0.20 ± 0.12 µg×mL-1, and 22.12 ± 14.46 µg×h×mL-1, respectively. The clinical efficiency was 55.6%, and the bacterial clearance rate was 77.8%. In the CRRT group, Cmax, Cmin, and AUC0-24 were 0.96 ± 0.31 µg×mL-1, 0.22 ± 0.12 µg×mL-1, and 19.90 ± 8.14 µg×h×mL-1, respectively. The clinical efficiency was 28.6%, and the bacterial clearance rate was 28.6%. The individual differences of tigecycline plasma concentrations in our study were widely variable, and the differences of the two groups' PK/PD parameters had no statistical significance (p < 0.05). CONCLUSION: CRRT may have had little influence in tigecycline metabolism in our study, and therapeutic drug monitoring needs to be introduced for critically ill patients because of various pharmacokinetic parameters.


Assuntos
Terapia de Substituição Renal Contínua , Antibacterianos , Estado Terminal , Humanos , Estudos Prospectivos , Tigeciclina
2.
Nan Fang Yi Ke Da Xue Xue Bao ; 37(1): 56-62, 2017 01 20.
Artigo em Zh | MEDLINE | ID: mdl-28109099

RESUMO

OBJECTIVE: To investigate the effect of Hugan Qingzhi tablets on lipid metabolism and inflammation in rats fed on high-fat diet and explore the underlying mechanisms. METHODS: Sixty male Sprague-Dawley rats were randomly divided into 6 groups, namely HFD group (with high-fat diet and distilled water), control group (with normal diet and distilled water), fenofibrate group (with high-fat diet and treatment with 0.1 g

Assuntos
Proteínas Quinases Ativadas por AMP/metabolismo , Medicamentos de Ervas Chinesas/farmacologia , Fígado/efeitos dos fármacos , Hepatopatia Gordurosa não Alcoólica/metabolismo , Fator de Transcrição RelA/metabolismo , Animais , Citocinas/metabolismo , Dieta Hiperlipídica , Fenofibrato , Hiperlipidemias/tratamento farmacológico , Hipolipemiantes , Inflamação/tratamento farmacológico , Fígado/metabolismo , Masculino , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Comprimidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA